Italian Anderson Fabry Disease Cardiovascular Registry
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Italian Anderson Fabry Disease Cardiovascular Registry, also known as the RICMAF Study, is a research project aimed at understanding Anderson-Fabry Disease (AFD), a rare condition that can affect the heart and other organs. Many people with AFD may not be diagnosed quickly because its symptoms can be vague, which can delay necessary treatment. By collecting information from a large number of patients across Italy, this study hopes to learn more about how AFD progresses, especially regarding heart health, and to improve care for those affected.
If you or someone you know has been diagnosed with AFD, you may be eligible to participate in this study if you are at least 2 years old and can provide consent. Participants will help researchers gather important information about the disease, including personal and family health history, as well as undergo tests to check for early signs of heart issues and other organ damage. This research could lead to better treatments and outcomes for people living with AFD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with Anderson Fabry disease
- • Age ≥ 2 years at diagnosis
- • Obtaining informed consent from the patient and parent or legal guardian.
- Exclusion Criteria:
- • - None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Arezzo, , Italy
Novara, , Italy
Lecce, , Italy
Parma, Pr, Italy
Pisa, , Italy
Roma, , Italy
Milano, , Italy
San Donato Milanese, , Italy
Reggio Emilia, , Italy
Messina, , Italy
Palermo, , Italy
Milano, , Italy
Bergamo, Bg, Italy
Bologna, , Italy
Genova, Ge, Italy
Udine, Ud, Italy
Trieste, Ts, Italy
Chieti, Abruzzo/Chieti, Italy
Potenza, Basilicata/Potenza, Italy
Brescia, Lombardia/Brescia, Italy
Milano, Lombardia/Milano, Italy
Milano, Lombardia/Milano, Italy
Milano, Lombardia/Milano, Italy
Milano, Lombardia/Milano, Italy
San Donato Milanese, Lombardia/Milano, Italy
Ancona, Marche/Ancona, Italy
Ancona, Marche/Ancona, Italy
Ivrea, Piemonte/Ivrea, Italy
Torino, Piemonte/Torino, Italy
Torino, Piemonte/Torino, Italy
Bari, Puglia/Bari, Italy
Foggia, Puglia/Foggia, Italy
Manfredonia, Puglia/Foggia, Italy
Lecce, Puglia/Lecce, Italy
Taranto, Puglia/Taranto, Italy
Cagliari, Sardegna/Cagliari, Italy
Cagliari, Sardegna/Cagliari, Italy
Catania, Sicilia/Catania, Italy
Messina, Sicilia/Messina, Italy
Palermo, Sicilia/Palermo, Italy
Arezzo, Toscana/Arezzo, Italy
Firenze, Toscana/Firenze, Italy
Pisa, Toscana/Pisa, Italy
Siena, Toscana/Siena, Italy
Trento, Trentino Alto Adige/Trento, Italy
Perugia, Umbria/Perugia, Italy
Padova, Veneto/Padova, Italy
Verona, Veneto/Verona, Italy
Caserta, , Italy
Catanzaro, , Italy
Cosenza, , Italy
Napoli, , Italy
Napoli, , Italy
Piacenza, , Italy
Reggio Calabria, , Italy
Rimini, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Salerno, , Italy
Chieti, , Italy
Potenza, , Italy
Brescia, , Italy
Milano, , Italy
Ancona, , Italy
Ancona, , Italy
Ivrea, , Italy
Torino, , Italy
Torino, , Italy
Bari, , Italy
Foggia, , Italy
Manfredonia, , Italy
Taranto, , Italy
Cagliari, , Italy
Cagliari, , Italy
Catania, , Italy
Firenze, , Italy
Siena, , Italy
Trento, , Italy
Perugia, , Italy
Padova, , Italy
Verona, , Italy
Patients applied
Trial Officials
Elena Biagini, MD, PhD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported